Biogen reports 52-week phase 2 data for lupus skin drug litifilimab
Tweet Send to a Friend
Biogen Inc. (Nasdaq: BIIB) announced 52-week results from the Phase 2 portion of its ongoing AMETHYST Phase 2/3 study evaluating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




